No annual revenue total was found in Cognition Therapeutics, Inc.'s SEC filings.
Cognition Therapeutics, Inc. (CGTX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Sep 30, 2026 it held $30.8 million in cash and investments and $489,000 in total debt.
Revenue
—
Net income (TTM)
$-15.99M
+42.9% vs year-ago TTM
Operating cash flow (TTM)
$-15.29M
+48.2% vs year-ago TTM
Free cash flow (TTM)
$-15.31M
EPS (TTM)
$-0.18
+61.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
89.35M
+44.2% vs prior year
Net cash
$30.27M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CGTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Purchase, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1455365
- Former names
- COGNITION THERAPUTICS INC (until Dec 28, 2010)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$47.8M | -$54.0M | -$50.7M | -$43.6M | -$28.6M |
| Net income | -$23.5M | -$34.0M | -$25.8M | -$21.4M | -$11.7M |
| Diluted EPS | -$0.32 | -$0.86 | -$0.86 | -$0.91 | -$3.13 |
| Operating cash flow | -$24.6M | -$28.5M | -$16.0M | -$18.5M | -$3.6M |
| Free cash flow | — | -$28.5M | -$16.2M | -$18.7M | -$3.7M |
| Total assets | $48.4M | $30.2M | $35.2M | $50.4M | $59.1M |
| Total liabilities | $14.1M | $11.5M | $10.7M | $10.2M | $7.9M |
| Stockholders' equity | $34.3M | $18.8M | $24.5M | $40.2M | $51.3M |
| Cash and investments | $36.8M | $25.0M | $29.9M | $41.6M | $54.7M |
| Total debt | $331,000 | $535,000 | $694,000 | $844,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Listing notice
|
Nov 5, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 22, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Other events
|
Jun 24, 2026 | Jun 24, 2026 |
All 303 Cognition Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.